Skip to main content

Advertisement

SpringerLink
Log in

Use of 5α-reductase inhibitors to prevent benign prostatic hyperplasia disease

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

A histologic change in the prostate, benign prostatic hyperplasia (BPH), is a normal part of aging. However, BPH disease, defined here as a life-altering urinary condition caused by BPH requiring prompt medical intervention, is a serious medical disorder associated with major complications, surgical intervention, and severe lifestyle interference. BPH disease is preventable. The rationale for BPH disease prevention rests on four pillars of evidence: (1) BPH disease generally is a progressive disorder; (2) complications and severe lifestyle interference from BPH disease are common and serious; (3) men at greatest risk of BPH disease can be identified using prostate-specific antigen (PSA) level higher than 1.5 ng/mL as a surrogate marker for an enlarged prostate; and (4) 5α-reductase inhibitors (5ARIs) reduce the primary androgen responsible for prostate growth (dihydrotestosterone), shrink the prostate, and arrest the disease process regardless of symptom status. Thus, we now can identify men with an enlarged prostate at risk for BPH disease who may be candidates for preventive therapy with 5ARIs, regardless of urinary symptoms or bother.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Andriole GL, Bruchovsky N, Chung LW, et al.: Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004, 172:1399–1403. This review article reported that DHT appeared to have an obligatory role in the development of BPH, and firmly established the role of 5ARIs in the treatment of BPH.

    Article  PubMed  CAS  Google Scholar 

  2. AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003, 170:530-547. This paper presents guidelines from the AUA, with recommendations regarding the diagnosis and treatment of benign prostatic hyperplasia.

  3. McConnell JD: Benign prostatic hyperplasia. J Urol 1994, 152:459–460.

    PubMed  CAS  Google Scholar 

  4. Marks LS: Treatment of men with minimally symptomatic benign prostatic hyperplasia-PRO: the argument in favor. Urology 2003, 62:781–783.

    Article  PubMed  Google Scholar 

  5. Kaplan SA: Medical therapy for asymptomatic men with benign prostatic hyperplasia: primum non nocere. Urology 2003, 62:784–785.

    Article  PubMed  Google Scholar 

  6. Girman CJ, Waldstreicher J: Prevention of the progression and long-term complications of benign prostatic hyperplasia. In Surgery of the Prostate. Edited by Resnick MI, Thompson IM. London: Churchill Livingstone; 1999:498-507.

    Google Scholar 

  7. Di Silverio F, Gentile V, Pastore AL, et al.: Benign prostatic hyperplasia: What about a campaign for prevention? Urol Int 2004, 72:179–188. In this article, arguments for the preventative treatment of BPH are presented to stimulate discussion of the topic. The authors conclude that more thorough investigation is necessary before a BPH prevention trial can be proposed.

    Article  Google Scholar 

  8. Kim ED: The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia. Curr Urol Rep 2004, 5:267–273.

    Article  PubMed  Google Scholar 

  9. McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398. In this long-term, double-blind, placebo-controlled trial, the effects of finasteride, doxazosin, and combination therapy are compared to measure their effects on the clinical progression of BPH. The study concluded that combination therapy with doxazosin and finasteride is safe and reduced the risk of overall clinical progression of BPH more significantly than did treatment with either drug alone.

    Article  PubMed  CAS  Google Scholar 

  10. Jacobsen SJ, Girman CJ, Lieber MM: Natural history of benign prostatic hyperplasia. Urology 2001, 58(suppl 6A):5–16.

    Article  PubMed  CAS  Google Scholar 

  11. Wright EJ, Fang J, Metter EJ, et al.: Prostate-specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 2002, 167:2484–2488.

    Article  PubMed  Google Scholar 

  12. Djavan B, Fong YK, Harik M, et al.: Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. J Urol 2004, 64:1144–1148.

    Article  Google Scholar 

  13. Girman CJ, Panser LA, Chute CG, et al.: Natural history of prostatism: urinary flow rates in a community-based study. J Urol 1993, 150:887–892.

    PubMed  CAS  Google Scholar 

  14. Rhodes T, Girman CJ, Jacobsen S, et al.: Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 70 years old. J Urol 1999, 161:1174–1179.

    Article  PubMed  CAS  Google Scholar 

  15. Jacobsen SJ, Jacobson DJ, Girman CJ, et al.: Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997, 158:481–487.

    Article  PubMed  CAS  Google Scholar 

  16. Arrighi HM, Metter EJ, Guess HA, et al.: Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 1991, 38(suppl):4–8.

    Article  PubMed  CAS  Google Scholar 

  17. Roehrborn CG, Malice MP, Cook TJ, Girman CJ: Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001, 58:210–216. Data from several prospective, randomized clinical trials were combined in this analysis. Findings indicated that prostate volume and serum PSA are strong predictors of AUR in placebo-treated men with LUTS and clinically diagnosed BPH who were screened for prostate cancer.

    Article  PubMed  CAS  Google Scholar 

  18. Iczkowski KA, Qiu J, Qian J, et al.: The dual 5-alphareductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 2005, 65:76–82.

    Article  PubMed  Google Scholar 

  19. McConnell JD, Bruskewitz R, Walsh P, et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-term Efficacy and Safety Study Group. N Engl J Med 1998, 338:557–563. This double-blind, randomized, placebo-controlled trial found that among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for 4 years reduced symptoms and prostate volume, increased the urinary flow rate, and reduced the risk of surgery and AUR.

    Article  PubMed  CAS  Google Scholar 

  20. Roehrborn CG, Boyle P, Nickel JC, et al.: Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:434–441. This study presents results from three identical clinical trials of 4325 men (2951 completed) who were randomized to receive 0.5 mg of dutasteride or placebo. Results indicated that dutasteride is a potent inhibitor of DHT production and is safe and effective in reducing prostate volume and symptoms, improving flow rate, and reducing the risk of AUR and surgery over 24 months.

    Article  PubMed  Google Scholar 

  21. Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224. This landmark study was the first to indicate that a drug can reduce a man’s chances of developing prostate cancer. Men taking finasteride were 25% less likely to develop prostate cancers than men in the placebo group. However, the incidence of high-grade tumors was greater in the men receiving finasteride.

    Article  PubMed  CAS  Google Scholar 

  22. Andriole GL, Roehrborn CG, Schulman C, et al.: Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004, 64:537–543.

    Article  PubMed  CAS  Google Scholar 

  23. Garraway WM, Russell EB, Lee RJ, et al.: Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993, 43:318–321.

    PubMed  CAS  Google Scholar 

  24. Girman CJ, Jacobsen SJ, Tsukamoto T, et al.: Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998, 51:428–436.

    Article  PubMed  CAS  Google Scholar 

  25. Lucas MG, Stephenson TP, Nargund V: Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 2005, 95:354–357.

    Article  PubMed  CAS  Google Scholar 

  26. Miller MI, Puchner PJ: Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology 1998, 51:237–240.

    Article  PubMed  CAS  Google Scholar 

  27. Hochberg DA, Basillote JB, Armenakas NA, et al.:Decreased suburethral prostatic microvessel density in finasteride-treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 2002, 167:1731–1733.

    Article  PubMed  CAS  Google Scholar 

  28. Winslow R: Avoiding the knife: prostate patients get choice of treatments that obviate surgery. Wall Street Journal 1990, 7:A1.

    Google Scholar 

  29. Bruchovsky N, Wilson JD: The intranuclear binding of testosterone and 5α-androstan-17β-ol-3-one by rat prostate. J Biol Chem 1968, 243:5953–5960.

    PubMed  CAS  Google Scholar 

  30. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE:Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974, 186:1213–1215.

    Article  PubMed  CAS  Google Scholar 

  31. Walsh PC, Madden JD, Harrod JL, et al.: Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974, 291:944–949.

    Article  PubMed  CAS  Google Scholar 

  32. Wilson JD: Dihydrotestosterone formation in cultured human fibroblasts: comparison of cells from normal subjects and patients with familial incomplete male pseudohermaphroditism, type 2. J Biol Chem 1975, 250:3498–3504.

    PubMed  CAS  Google Scholar 

  33. Moore RJ, Griffin JE, Wilson JD: Diminished 5α-reductase activity in extracts of fibroblasts cultured from patients with familial incomplete male pseudohermaphroditism, type 2. J Biol Chem 1975, 250:7168–7172.

    PubMed  CAS  Google Scholar 

  34. Moore RJ, Wilson JD: Steroid 5α-reductase in cultured human fibroblasts: biochemical and genetic evidence for two enzyme activities. J Biol Chem 1976, 251:5895–5900.

    PubMed  CAS  Google Scholar 

  35. Stoner E: The clinical development of a 5alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990, 37:375–378.

    Article  PubMed  CAS  Google Scholar 

  36. Gormley GJ, Stoner E, Bruskewitz RC, et al.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992, 327:1185–1191.

    Article  PubMed  CAS  Google Scholar 

  37. Clark RV, Hermann DJ, Cunningham CR, et al.: Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004, 89:2179–2184.

    Article  PubMed  CAS  Google Scholar 

  38. Roehrborn CG, McConnell JD, Lieber M, et al.: Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999, 53:581–589. This analysis of placebo-controlled, multicenter trials of 4627 patients indicated that prostate volume is strongly related to serum PSA in men with BPH and no evidence of prostate cancer, and the relationship depends on age. In addition, the study found that serum PSA can estimate the degree of prostate enlargement with sufficient accuracy to be useful for therapeutic decision-making.

    Article  PubMed  CAS  Google Scholar 

  39. Roehrborn CG, McConnell JD, Lieber MM, et al.: Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999, 53:473–480. This randomized, 4-year study of 3040 men found that serum PSA and prostate volume are powerful predictors of the risk of AUR and the need for BPH-related surgery in men with BPH.

    Article  PubMed  CAS  Google Scholar 

  40. Stamey TA, Caldwell M, McNeal JE, et al.: The prostatespeci fic antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 2004, 172:1297–1301.

    Article  PubMed  Google Scholar 

  41. Williams AM, Simon I, Landis PK, et al.: Prostatic growth rate determined from MRI data: age-related longitudinal changes. J Androl 1999, 20:474–480.

    PubMed  CAS  Google Scholar 

  42. Lytton B, Emery JM, Harvard BM: The incidence of benign prostatic obstruction. J Urol 1968, 99:639–645.

    PubMed  CAS  Google Scholar 

  43. Barry MJ, Fowler FJ, Bin L, et al.: The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 1997, 157:10–14.

    Article  PubMed  CAS  Google Scholar 

  44. Meigs JB, Barry MJ, Giovannucci E, et al.: Incidence rates and risk factors for acute urinary retention: the Health Professionals Follow-up Study. J Urol 1999, 162:376–382.

    Article  PubMed  CAS  Google Scholar 

  45. Roehrborn CG, Boyle P, Bergner D, et al.: Serum prostatespeci fic antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a 4-year, randomized trial comparing finasteride versus placebo. Urology 1999, 54:662–669.

    Article  PubMed  CAS  Google Scholar 

  46. Bosch JL, Bohnen AM, Groeneveld FP: Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in communitybased men aged 50 to 78 years: the Krimpen Study. Eur Urol 2004, 46:753–759.

    Article  PubMed  CAS  Google Scholar 

  47. Lepor H, Williford WO, Barry MJ, et al.: The Efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996, 335:533–539.

    Article  PubMed  CAS  Google Scholar 

  48. Price H, McNeal JE, Stamey TA: Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum Pathol 1990, 21:578–585.

    Article  PubMed  CAS  Google Scholar 

  49. Carter HB, Landis P, Wright EJ, et al.: Can a baseline prostate-specific antigen level identify men who will have lower urinary tract symptoms later in life? J Urol 2005, 173:2040–2043.

    Article  PubMed  CAS  Google Scholar 

  50. Marks LS, Hess DL, Dorey FJ, et al.: Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001, 57:999–1005.

    Article  PubMed  CAS  Google Scholar 

  51. Roehrborn CG, Marks LS, Fenter T, et al.: Efficacy and safety of dutasteride in the 4-year treatment of men with benign prostatic hyperplasia. Urology 2004, 63:709–715. This pooled analysis of two multicenter, randomized, placebo-controlled trials reported that treatment with the dual 5ARI dutasteride provided sustained improvements in urinary symptoms and peak flow rate and was well tolerated over 4 years in men with BPH.

    Article  PubMed  Google Scholar 

  52. Andriole GL, Humphrey P, Ray P, et al.: Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004, 172:915–919.

    Article  PubMed  CAS  Google Scholar 

  53. Marks LS, Partin AW, Dorey FJ, et al.: Long-term effects of finasteride on prostate tissue composition. Urology 1999, 53:574–580.

    Article  PubMed  CAS  Google Scholar 

  54. Kaplan SA, Garvin D, Gilhooly P, et al.: Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. Urology 2000, 56:610–616.

    Article  PubMed  CAS  Google Scholar 

  55. Andriole GL, Kirby R: Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003, 44:82–88.

    Article  PubMed  CAS  Google Scholar 

  56. Bostwick DG, Qian J, Civantos F, et al.: Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2004, 2:228–235.

    PubMed  CAS  Google Scholar 

  57. Thompson IM: New insights and developments from the Prostate Cancer Prevention Trial: the promise of SELECT. http://webcasts.prous.com/aua2005. Accessed July 19, 2005.

  58. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC/ AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002, 40:567–572.

    Article  PubMed  Google Scholar 

  59. Coogan CL, Latchamsetty KC, Greenfield J, et al.:Increasing the number of biopsy cores improves the concordance of biopsy Gleason score to prostatectomy Gleason score. BJU Int 2005, 96:324–327.

    Article  PubMed  Google Scholar 

  60. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8–29.

    Article  PubMed  Google Scholar 

  61. Etzioni RD, Howlader N, Shaw PA, et al.: Long-term effects of finasteride on prostate-specific antigen levels: results from the Prostate Cancer Prevention Trial. J Urol 2005, 174:877–881.

    Article  PubMed  CAS  Google Scholar 

  62. Kaplan SA, Ghafar MA, Volpe MA, et al.: PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/mL and previous negative prostate biopsy: preliminary study. Urology 2002, 60:464–468.

    Article  PubMed  Google Scholar 

  63. US Census Bureau, Population Projections Program, Population Division. (NTB-T3-B) Projections of the Total Resident Population by 5-year Age Groups, and Sex with Special Age Categories: Middle Series, 2001 to 2005. http://www.census.gov/population/projections/nation/ summary/np-t3-b.txt. Accessed May 2, 2006.

  64. Berry SJ, Coffey DS, Walsh PC, et al.: The development of human benign prostatic hyperplasia with age. J Urol 1984, 132:474–479.

    PubMed  CAS  Google Scholar 

  65. Sarma AV, Wei JT, Jacobson DJ, et al.: Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of urinary symptoms and health status and the Flint Men’s Health Study. Urology 2003, 61:1086–1091.

    Article  PubMed  Google Scholar 

  66. Wasson JH, Bubolz TA, Yao GL, Barry MJ: Prostate biopsies in men with limited life expectancy. Effect Clin Pract 2002, 5:137–142.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Geffen School of Medicine at UCLA, Urological Sciences Research Foundation, 3831 Hughes Avenue, 90232, Culver City, CA, USA

    Leonard S. Marks MD

Authors
  1. Leonard S. Marks MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonard S. Marks MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marks, L.S. Use of 5α-reductase inhibitors to prevent benign prostatic hyperplasia disease. Curr Urol Rep 7, 293–303 (2006). https://doi.org/10.1007/s11934-996-0009-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-996-0009-x

Keywords

Search

Navigation